The company will be judged by the results of its peers, and it might not compare as well as shareholders hope.
CRISPR Therapeutics AG (CRSP) News
Latest headlines that mention CRSP, newest first · each headline opens the original publisher
- Last price
- $50.44
- Day change
- -3.65%
- Next earnings
- 2026-11-09
CRSP headlines
last 30 daysOne is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.
With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Also mentioned with CRSP
30dHeadlines that tag both tickers
CRSP news alerts
Get an alert by email or push when a new headline mentions CRSP.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.